Avidity Biosciences, Inc.

NasdaqGM:RNA 주식 보고서

시가총액: US$5.0b

Avidity Biosciences 관리

관리 기준 확인 2/4

Avidity Biosciences CEO는 Sarah Boyce, Oct2019 에 임명되었습니다 의 임기는 5.08 년입니다. 총 연간 보상은 $ 11.14M, 5.7% 로 구성됩니다. 5.7% 급여 및 94.3% 보너스(회사 주식 및 옵션 포함). 는 $ 3.04M 가치에 해당하는 회사 주식의 0.06% 직접 소유합니다. 3.04M. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 5.2 년입니다.

주요 정보

Sarah Boyce

최고 경영자

US$11.1m

총 보상

CEO 급여 비율5.7%
CEO 임기5.1yrs
CEO 소유권0.06%
경영진 평균 재임 기간3.8yrs
이사회 평균 재임 기간5.2yrs

최근 관리 업데이트

Recent updates

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Oct 02

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14
Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Aug 11
Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Jun 14

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

May 19

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04
Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Avidity slips 20% as FDA places lead asset on partial clinical hold

Sep 27

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Jul 29
We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Avidity stock rises amid Chardan starting coverage with Buy

Jul 20

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Jul 12

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Mar 26
We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Avidity Biosciences: Risks And Potential

Dec 09

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Nov 30
We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

CEO 보상 분석

Sarah Boyce 의 보수는 Avidity Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$280m

Jun 30 2024n/an/a

-US$252m

Mar 31 2024n/an/a

-US$229m

Dec 31 2023US$11mUS$635k

-US$212m

Sep 30 2023n/an/a

-US$202m

Jun 30 2023n/an/a

-US$193m

Mar 31 2023n/an/a

-US$192m

Dec 31 2022US$5mUS$601k

-US$174m

Sep 30 2022n/an/a

-US$162m

Jun 30 2022n/an/a

-US$148m

Mar 31 2022n/an/a

-US$128m

Dec 31 2021US$6mUS$570k

-US$118m

Sep 30 2021n/an/a

-US$96m

Jun 30 2021n/an/a

-US$78m

Mar 31 2021n/an/a

-US$62m

Dec 31 2020US$823kUS$484k

-US$44m

Sep 30 2020n/an/a

-US$38m

Jun 30 2020n/an/a

-US$34m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$4mUS$104k

-US$25m

보상 대 시장: Sarah 의 총 보상 ($USD 11.14M )은 US 시장( $USD 7.91M ).

보상과 수익: 회사가 수익성이 없는 동안 Sarah 의 보상이 증가했습니다.

CEO

Sarah Boyce (52 yo)

5.1yrs

테뉴어

US$11,139,719

보상

Ms. Sarah Boyce is Director of Abcuro, Inc. from July 2024. She serves as Independent Director of Contineum Therapeutics, Inc Since June 2024. She has been President, Chief Executive Officer and Director a...

리더십 팀

이름위치테뉴어보상소유권
Troy Wilson
Co-Founder & Independent Chairman12yrsUS$260.31k0.064%
$ 3.2m
Sarah Boyce
President5.1yrsUS$11.14m0.060%
$ 3.0m
Michael MacLean
Chief Financial & Chief Business Officer4.5yrsUS$4.48m0.0065%
$ 325.6k
W. Michael Flanagan
Chief Scientific & Technical Officer3.8yrsUS$4.89m0.072%
$ 3.6m
Teresa McCarthy
Chief Human Resources Officer4.3yrsUS$3.73m0.079%
$ 4.0m
Arthur Levin
Distinguished Scientist1.8yrsUS$3.03m0.13%
$ 6.5m
Eric Mosbrooker
Chief Strategy Officerless than a yearUS$235.31k0%
$ 0
Mark Davis
Scientific Founder12.8yrs데이터 없음데이터 없음
Frank McCormick
Scientific Founder & Member of Scientific Advisory Board12.8yrs데이터 없음데이터 없음
John Moriarty
Chief Legal Officer & Corporate Secretaryless than a year데이터 없음데이터 없음
John Wallen
Consultantless than a year데이터 없음데이터 없음
Kathleen Gallagher
Chief Program Officer1.8yrs데이터 없음데이터 없음

3.8yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: RNA 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Troy Wilson
Co-Founder & Independent Chairman12yrsUS$260.31k0.064%
$ 3.2m
Sarah Boyce
President5.1yrsUS$11.14m0.060%
$ 3.0m
Arthur Levin
Distinguished Scientist1.8yrsUS$3.03m0.13%
$ 6.5m
Mark Davis
Scientific Founderno data데이터 없음데이터 없음
Frank McCormick
Scientific Founder & Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Carsten Boess
Independent Director4.6yrsUS$245.31k0%
$ 0
Richard Heyman
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Edward Kaye
Independent Director5.3yrsUS$244.31k0%
$ 0
Eran Nadav
Observerno data데이터 없음데이터 없음
Christopher Kirk
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Noreen Henig
Independent Director5.3yrsUS$245.81k0%
$ 0
Ryan Corcoran
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

5.2yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 이사회: RNA 의 이사회는 경험(평균 재직 기간 5.2 년)으로 간주됩니다.